Turing Medical Introduces Advanced Brain Mapping and Targeting Solution at ASSFN Biannual Meeting

Monday, June 03, 2024

Turing Medical, a leading innovator in precision neuromodulation therapies, has introduced Bullsai, a cutting-edge brain mapping and targeting solution, at the American Society for Stereotactic and Functional Neurosurgery (ASSFN) Biennial Meeting in Nashville, Tennessee.

While pending FDA clearance, Bullsai is now available for research use, marking a significant advancement in precise brain mapping and targeting in neuromodulation therapy.

Neuromodulation therapies like Deep Brain Stimulation (DBS) and Focused Ultrasound are revolutionizing treatments for neurological disorders such as Parkinson’s disease and essential tremor, and they hold potential for various other neuropsychiatric conditions.

Achieving precise targeting of brain nodes and networks is essential for optimal results and minimizing side effects. However, current coordinate-based strategies often overlook the variability in brain structure and function between patients.

Turing Medical has addressed this with an advanced MRI processing pipeline that identifies neuroanatomical structures, white matter pathways, and functional brain networks, allowing for individualized targeting.

UCSF neuroradiologist and neuroscientist, commented, “Bullsai makes advanced imaging accessible for targeting image-guided neuromodulation tailored to each patient's brain structure and function.

This solution enables clinicians to accurately pinpoint brain regions with millimeter-level precision, integrating advanced imaging into clinical workflows to improve outcomes and free up clinicians to focus on patient care.”

Enhanced Personalized Precision Targeting

Turing Medical's Bullsai enhances neuromodulation therapies by integrating precise, personalized image-based targeting into clinical workflows. Its sophisticated image processing and analysis pipelines identify treatment targets and provide metrics for target accuracy and confidence, streamlining pre-operative planning, saving time, improving patient outcomes, and reducing off-target effects.

  • Precision Targeting: Enables clinicians to target specific brain nodes and networks, personalizing treatment for improved and predictable outcomes.
  • Streamlined Workflows: Automated workflows simplify advanced image-guided targeting, providing clinicians with necessary information for personalized targeting and efficient planning and execution of neuromodulation procedures.
  • Better Clinical Outcomes: Personalized targeting and automated workflows aim to enhance neuromodulation therapies by improving patient outcomes and minimizing adverse side effects.

Pending FDA clearance, Turing Medical's Bullsai is available for research purposes only.






Harvard Medical School - Leadership in Medicine Southeast Asia47th IHF World Hospital CongressHealthcare CNO Summit - USAHealthcare CMO Summit - USAHealthcare CFO, Financial Strategy & Revenue Cycle SummitHealthcare CEO & Executive Strategy Summit